Iovance Biotherapeutics Inc.

# SIGNAL NOTE: Perceptive Advisors Initiates IOVA Position Perceptive's entry into Iovance signals conviction in lifileucel's commercial potential following its September 2023 FDA approval for advanced melanoma. The $417K position (modest for Perceptive's scale) suggests selective conviction rather than portfolio-wide enthusiasm, likely tracking toward 2024 label expansion data in other solid tumors where TIL therapy efficacy remains unproven.